Development of a mutant human coagulation protein as a novel antidote for new direct factor Xa anticoagulant drugs, and as a tool for investigating the activity and regulation of intrinsic and extrinsic tenase, key enzyme complexes in blood coagulation.

开发突变型人类凝血蛋白，作为新型直接 Xa 因子抗凝血药物的新型解毒剂，并作为研究凝血中关键酶复合物内在和外在 Tenase 的活性和调节的工具。

• 批准号: 278235
• 负责人: Yeh Calvin H
• 金额: $ 0.04万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2013-04-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=278235&lang=en
• 关键词: Anticoagulation; Antithrombin; Coagulation; Enzyme Kinetics; Factor Xa; Fondaparinux; Hemophilia; Heparin; Ics Travel Awards; Thrombin

Heart attacks and strokes, the number one cause of death and disability in Canada, are often caused by defective blood clotting in the human body. This research project aims to translate discoveries made on the scientific bench to the bedside by figuring

心脏病和中风是加拿大死亡和残疾的第一大原因，通常是由人体内凝血缺陷引起的。该研究项目旨在通过计算将科学台上的发现转化为临床